DelveInsight’s “PDE4B Inhibitor Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the PDE4B inhibitor, historical and projected epidemiological data, competitive landscape as well as the PDE4B inhibitor therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the PDE4B Inhibitors Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/pde4b-inhibitors-market-forecast
Key Takeaways from the PDE4B Inhibitors Market Report
- As per DelveInsight’s analysis, the total market size of PDE4B inhibitors in the leading markets (the US, EU4, UK, and Japan) is expected to surge significantly by 2034.
- The leading PDE4B inhibitor Companies, such as Chiesi Farmaceutici, Alto Neuroscience, MEDRx, and others.
- Promising PDE4B inhibitors Therapies such as Tanimilast (CHF6001), ALTO-101, and others.
Stay ahead in the PDE4B Inhibitors Therapeutics Market with DelveInsight’s Strategic Report @ PDE4B Inhibitors Market Outlook
PDE4B Inhibitors Epidemiology Segmentation in the 7MM
- Total Cases in Selected Indications for PDE4B Inhibitor
- Total Eligible Patient Pool in Selected Indications for PDE4B Inhibitor
- Total Treated Cases in Selected Indications for PDE4B Inhibitor
Download the report to understand which factors are driving PDE4B Inhibitors Epidemiology trends @ PDE4B Inhibitors Prevalence
PDE4B Inhibitors Marketed Drugs
- OHTUVAYRE (ensifentrine): Verona Pharma
OHTUVAYRE (ensifentrine) is an inhaled small-molecule therapy that acts as a dual inhibitor of PDE3 and PDE4, enzymes responsible for hydrolyzing cAMP and, in the case of PDE3, also cGMP. By blocking these pathways, ensifentrine increases intracellular cAMP and cGMP levels, leading to both bronchodilatory and anti-inflammatory effects. Delivered as an inhalation suspension, it is approved for the maintenance treatment of COPD in adults, offering a novel approach that combines dual-mechanism activity within a single therapy. Verona Pharma is expanding the clinical scope of ensifentrine beyond COPD, with ongoing Phase II trials evaluating its potential across multiple respiratory indications. The nebulized formulation is being studied for NCFB, cystic fibrosis, and asthma, while Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) formulations are under evaluation for maintenance treatment in COPD, cystic fibrosis, and asthma. Additionally, a nebulized combination of ensifentrine with LAMA is being explored for maintenance treatment of COPD, highlighting the company’s strategy to position ensifentrine as a versatile therapy across diverse respiratory diseases and delivery platforms.
- ZORYVE (roflumilast): Arcutis Biotherapeutics
ZORYVE (roflumilast) is a PDE4 inhibitor that increases intracellular cAMP levels by blocking the enzyme responsible for its breakdown, thereby modulating inflammatory pathways central to dermatologic diseases. While the exact mechanism of action remains not fully defined, its clinical utility has been established across multiple indications. ZORYVE cream 0.3% is approved for plaque psoriasis, including intertriginous areas, in patients 6 years and older, while the 0.15% cream is indicated for mild to moderate atopic dermatitis in the same age group. Additionally, ZORYVE topical foam 0.3% is approved for seborrheic dermatitis in patients 9 years and older and for plaque psoriasis of the scalp and body in patients 12 years and older, underscoring its broad therapeutic potential in chronic inflammatory skin conditions. Additionally, ZORYVE is being evaluated as a 0.05% formulation for atopic dermatitis in younger pediatric populations, specifically in children aged 2–5 years and infants aged 3–24 months.
- EUCRISA (crisaborole): Pfizer
EUCRISA (crisaborole) is a topical PDE4 inhibitor that enhances intracellular cAMP levels, thereby modulating inflammatory responses implicated in atopic dermatitis, although its precise therapeutic mechanism remains unclear. It is approved for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients as young as 3 months, making it one of the earliest treatment options available for this condition across a wide age spectrum.
PDE4B Inhibitors Emerging Drugs
- Tanimilast (CHF6001): Chiesi Farmaceutici
CHF6001 is an inhaled anti-inflammatory therapy under development for COPD and asthma. As a PDE4 inhibitor, it blocks the degradation of intracellular cAMP in inflammatory cells, thereby suppressing inflammation and modulating immune activity. This mechanism is designed to reduce airway inflammation, relieve symptoms, and improve lung function in patients with chronic respiratory disease. The drug is currently in Phase III trials for COPD and Phase II trials for asthma.
- ALTO-101: Alto Neuroscience/MEDRx
ALTO-101 is an innovative small molecule designed to treat CIAS. As a brain-penetrant PDE4 inhibitor, it targets the enzyme responsible for breaking down cAMP, a crucial intracellular signaling molecule involved in cognition and neuroplasticity. PDE4 inhibitors have been studied for their potential pro-cognitive and antidepressant effects, making ALTO-101 a promising candidate for CIAS treatment. The drug utilizes a Transdermal Delivery System (TDS), which helps reduce the adverse events typically seen with PDE4 inhibitors, allowing for higher, more effective doses guided by EEG and behavioral biomarker readouts.
PDE4B Inhibitors Market Outlook
The market outlook for PDE4B inhibitors is gaining momentum as the class shows strong therapeutic potential across respiratory, dermatologic, and inflammatory conditions. Approved drugs like OHTUVAYRE (ensifentrine), ZORYVE (roflumilast), and EUCRISA (crisaborole), among others, have already validated the PDE4 pathway, while emerging candidates such as tanimilast (CHF6001) and ALTO-101, among others, are expanding opportunities into more targeted and differentiated indications. With growing demand for safer, orally active, and more selective anti-inflammatory therapies, PDE4B inhibitors are well positioned to capture increasing market share, particularly as unmet needs in COPD, asthma, and immune-mediated diseases continue to drive innovation.
Get In-Depth Knowledge on PDE4B Inhibitors Market Trends and Forecasts with DelveInsight @ PDE4B Inhibitors Treatment Market
PDE4B Inhibitors Companies
Chiesi Farmaceutici, Alto Neuroscience, MEDRx
PDE4B Inhibitors Market Analysis
PDE4B inhibitors present significant multi-indication potential in respiratory, dermatologic, and neuropsychiatric disorders, offering both clinical relevance and commercial opportunity. This positions them as a distinct therapeutic class capable of driving sustained market growth. The success of currently approved PDE4-targeting therapies, including OHTUVAYRE (ensifentrine), ZORYVE (roflumilast), and EUCRISA (crisaborole), underscores the therapeutic importance of PDE4 modulation, validating its commercial value while demonstrating its expanding role across diverse clinical settings. OHTUVAYRE (ensifentrine) is an inhaled small-molecule dual inhibitor of PDE3 and PDE4, enzymes that degrade cAMP and, in the case of PDE3, cGMP. By blocking these pathways, ensifentrine increases intracellular cAMP and cGMP, resulting in bronchodilatory and anti-inflammatory effects. Approved as an inhalation suspension for maintenance treatment of COPD in adults, it introduces a differentiated dual-mechanism approach within a single therapy.
Scope of the PDE4B Inhibitors Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- PDE4B Inhibitors Companies- Chiesi Farmaceutici, Alto Neuroscience, MEDRx and others.
- PDE4B Inhibitors Therapies- Tanimilast (CHF6001), ALTO-101, and others.
- PDE4B Inhibitors Therapeutic Assessment: PDE4B Inhibitors current marketed and PDE4B Inhibitors emerging therapies
- PDE4B Inhibitors Market Dynamics: PDE4B Inhibitors market drivers and PDE4B Inhibitors market barriers
- PDE4B Inhibitors Unmet Needs, KOL’s views, Analyst’s views, PDE4B Inhibitors Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive PDE4B Inhibitors Market Report @ PDE4B Inhibitors Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Market Forecast Methodology
6 Market Overview at a Glance in the 7MM
7 PDE4B Inhibitor: Background and Overview
8 Target Patient Pool
9 PDE4B Inhibitor Marketed Therapies
10 PDE4B Inhibitor Emerging Therapies
11 PDE4B Inhibitor: The 7MM Analysis
12 PDE4B Inhibitor Unmet Needs
13 SWOT Analysis
14 KOL Views
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
